With five global central laboratories, Labcorp understands the value of around-the-clock support to advance clinical trial testing, but the recent 65-day lockdown at their Shanghai facilities gave new meaning to “around the clock.” Understanding the severity of the situation On March 28, 2022, the entire population of Shanghai was suddenly …
Business continuity: how robust is your patient support disaster relief plan?
Weathering natural disasters and the COVID-19 pandemic To drive speed to therapy, reduce financial burdens and empower patient engagement, a Patient Support Services Call Center provides myriad support services that stakeholders depend upon. For pharmaceutical manufacturers, these services have gone from “nice to have” to “must-have,” driven by the growth …
Optimizing in vivo respiratory model studies
In vivo respiratory disease models are valuable in the identification of potential medications targeted at treating human respiratory diseases. Common respiratory diseases include lung fibrosis or the emerging COVID-19, where highly efficacious treatments are limited and where in vivo disease models can help to screen for potential new treatments. In …
Using acute respiratory disease syndrome (ARDS) in vivo models to screen for coronavirus inflammation treatment
Solutions to the current COVID-19 pandemic involve preventing coronavirus infection through vaccination and treating the severe clinical symptoms of the disease, including acute respiratory distress syndrome (ARDS). Establishing in vitro screening for potential treatments, though, can be challenging, due to the limited number of appropriate research models available, and the …
The COVID-19 road to recovery: coordinating clinical trial testing and central lab solutions
As COVID-19 was declared a pandemic, our Clinical Trials Testing Solutions (CTTS) witnessed a sudden influx of COVID-19 studies from both large pharmaceutical organizations and biotechs. Not only did CTTS need to accelerate the timelines for these drug development sponsors’ urgent studies, but they needed to provide patient-centric testing solutions, …
Immunogenicity studies for the coronavirus vaccines: How to stay on track and build testing capacity even during COVID-19
As the world waits for a vaccine to protect against COVID-19, the disease caused by the novel coronavirus, it will need not only scientific excellence but also business continuity excellence to keep vital research and immunogenicity studies running. Vaccine development relies on many early, nonclinical studies; some of the earliest …
Patient Intelligence: designing clinical trials in the COVID-19 era
In the age of COVID-19, patients can’t wait for new vaccines and therapies to come to the market. That is why even in these challenging times, we have been focused more than ever on understanding the patient perspective on clinical trial participation. As social distancing has become the new normal, …
Labcorp delivers unmatched COVID-19 diagnostic and therapeutic applications
We’re in this together: How they are delivering unmatched acceleration of COVID-19 diagnostic and therapeutic applications Accelerating much needed COVID-19 testing, vaccines and treatment options across the world can’t be done alone. We’re in this together and ready to apply our unique combination of solutions that blend Covance and Labcorp’s …